drugset / Trial / NCT00712101

Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction

NCT00712101 ↗

Phase 3 Completed 1912 enrolled University of Leipzig
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to examine whether intracoronary abciximab bolus application with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus application with respect to 90-day mortality, reinfarction and new congestive heart failure.

Timeline

Start
2008-07
Primary completion
2011-04
Completion
2011-04

Outcome

Missed primary endpoint

paper Intracoronary, as compared with intravenous abciximab, resulted in a similar rate of the primary composite clinical endpoint at 90 days PMID 22357109 ↗

paper 7·0%vs 7·6%; odds ratio [OR] 0·91; 95% CI 0·64-1·28; p=0·58 PMID 22357109 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abciximab Monoclonal antibody 0.125 ug/kg Intravenous